Patents by Inventor José Maria Jimeno Donaque

José Maria Jimeno Donaque has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Improved Antitumoral Treatments
    Publication number: 20100240595
    Abstract: The present invention relates to combinations of Aplidine with Gemcitabine, and the use of these combinations in the treatment of cancer.
    Type: Application
    Filed: October 20, 2008
    Publication date: September 23, 2010
    Applicant: PHARMA MAR ,S.A.
    Inventors: Giuseppe Longo Sorbello, Pravin Jaiprakash Mishra, Prasun Jaiprakash Mishra, Joseph Rocco Bertino, Debabrata Banerjee, José Maria Jimeno Donaque
  • Antitumoral Treatments
    Publication number: 20100226919
    Abstract: The present invention relates to combinations of PM02734 with EGFR tyrosine kinase inhibitors, and the use of these combinations in the treatment of cancer.
    Type: Application
    Filed: October 17, 2008
    Publication date: September 9, 2010
    Applicants: Pharma Mar, S.A., ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Román Pérez-Soler, Yi-He Ling, José Maria Jimeno Donaque, Yi-Yu Zou
  • Prognostic Molecular Markers
    Publication number: 20080293725
    Abstract: The present invention relates to the use of ecteinascidin 743 in patients having certain levels of molecular markers who can predict the outcome of chemotherapy, in particular in patients having low levels of BRCA1 expression.
    Type: Application
    Filed: July 11, 2005
    Publication date: November 27, 2008
    Inventors: Rafael Rosell Costa, Miguel Taron Roca, Jose Maria Jimeno Donaque, Juan Carlos Tercero Lopez
  • Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
    Publication number: 20080255132
    Abstract: Methods of treating a human body for cancer are provided. In one aspect, an effective therapeutic amount of paclitaxel is administered in combination with ET-743 in a dose range between 0.5 and 1 mg/m2. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with paclitaxel in a dose range between 80 and 140 mg/m2.
    Type: Application
    Filed: October 28, 2004
    Publication date: October 16, 2008
    Inventors: Eric Rowinsky, Quincy Siu-Ching Chu, Jose Maria Jimeno Donaque, Luis Lopez Lazaro